-

10:58:46 PM

OCGN Stock News

OCGN - Ocugen Inc

09/29/23 7:30 AM

Nasdaq : OCGN

conferences

Ocugen CSO to Participate in 4th Annual Gene Therapy for Ophthalmic Disorders Conference

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Arun Upadhyay, PhD, Ocugen’s Chief

RHEA-AI

neutral

09/27/23 7:30 PM

Nasdaq : OCGN

conferences

Ocugen to Participate in Fireside Chat at Chardan’s 7th Annual Genetic Medicines Conference

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief

RHEA-AI

neutral

09/21/23 7:30 AM

Nasdaq : OCGN

management

Ocugen, Inc. Announces Connie Collingsworth Joins Business Advisory Board

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Connie Collingsworth, former Chief

RHEA-AI

neutral

09/20/23 8:00 AM

Nasdaq : OCGN

conferences

Ocugen to Participate in Panel at Cantor Fitzgerald Global Healthcare Conference 2023

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief

RHEA-AI

neutral

09/13/23 8:15 AM

Nasdaq : OCGN

clinical trial

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

Favorable safety and tolerability profile of OCU400 investigational drug product in RP and LCA subjects to date Clinical study update suggests continued positive trends in Best-Corrected Visual Acuity (BCVA) and Multi-Luminance Mobility Testing (MLMT), as well as positive trends in Low-Luminance

RHEA-AI

positive

09/12/23 7:30 PM

Nasdaq : OCGN

conferences

Ocugen to Host Virtual Investor & Analyst Event on September 13, 2023

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering,

RHEA-AI

neutral

08/21/23 4:32 PM

Nasdaq : OCGN

earnings

Ocugen Provides Business Update with Second Quarter 2023 Financial Results

Conference Call and Webcast Tomorrow at 8:30 a.m. ET • Investigational New Drug (IND) Applications Cleared for Novel Gene Therapies for Geographic Atrophy Secondary to AMD and for Stargardt Disease • OCU400 Clinical Study Results Update Expected This Quarter MALVERN, Pa., Aug. 21, 2023 (GLOBE

RHEA-AI

neutral

08/18/23 4:39 PM

Nasdaq : OCGN

conferencesearnings

Ocugen to Host Conference Call on Tuesday, August 22 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2023 Financial Results

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that it will host a conference call and live

RHEA-AI

neutral

06/30/23 8:00 AM

Nasdaq : OCGN

conferences

Ocugen CEO & CSO to Present at 41st Annual AAPI Convention and Scientific Assembly

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s Chairman, CEO and

RHEA-AI

neutral

06/09/23 4:05 PM

Nasdaq : OCGN

Ocugen, Inc. Announces Adjournment of Annual Meeting of Shareholders

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Company’s 2023 Annual Meeting of

RHEA-AI

neutral

1 2 3 4 5 6 7 8 9 10 Next

OCGN Data

IndustrySanitary Paper Product Manufacturing
Websitehttp://www.histogenics.com/
Security nameOcugen Inc
SectorManufacturing
Tags
- Health Technology
- Biotechnology
- Pharmaceuticals: Major
- Manufacturing
- Sanitary Paper Product Manufacturing
CountryUS

About Ocugen Inc

ocugen, inc., is a rapidly growing ophthalmology company developing a rich clinical pipeline of innovative therapies that address rare and underserved ocular disorders. the company’s lead programs in ocular graft versus host disease (ocu300) and chronic dry eye disease (ocu310) are expected to enter pivotal clinical trials in 2018. ocu300 received the first and only orphan drug designation for ocular graft versus host disease, providing certain regulatory and economic benefits. ocugen is also developing novel biologic therapies for retinitis pigmentosa (ocu100) and wet amd (ocu200), as well as a groundbreaking modifier gene therapy platform with potential to address a broad spectrum of inherited retinal disorders (ocu400). for more information, please visit www.ocugen.com.